Form 4: Nuvalent's Chief Legal Officer, Deborah Ann Miller, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc., exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan on August 8, 2024.

Summary

• On August 8, 2024, Deborah Ann Miller, the Chief Legal Officer of Nuvalent, Inc., engaged in transactions involving the company's Class A Common Stock.
• Miller exercised a stock option to acquire 3,000 shares at a price of $6.89 per share.
• Simultaneously, Miller sold a total of 3,000 shares acquired from the option exercise.
• Additionally, Miller sold 112 shares at $65.66, 624 shares at $67.17, 96 shares at $67.95, 1,794 shares at $69.34 and 374 shares at $69.95.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Miller directly owns 33,300 shares of Class A Common Stock and holds options for 176,608 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing reflects routine transactions under a pre-arranged trading plan. No indication of positive or negative implications for the company's performance.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Comparing Deborah Ann Miller's transactions to those of other Chief Legal Officers in similar biotech companies would require analyzing their Form 4 filings.
• The volume of shares traded and the use of 10b5-1 plans are typical aspects to benchmark against industry peers.
• Specific companies like Relay Therapeutics, Black Diamond Therapeutics, or Kinnate Biopharma could serve as comparables, but a detailed analysis of their insider trading activity would be needed.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates